Infection with SARS-CoV-2 causes flares in patients with juvenile idiopathic arthritis in remission or inactive disease on medication

Abstract Background Flares of juvenile idiopathic arthritis (JIA) have been described in the context of various infections. Flares of rheumatic diseases in adults have been described following infection with SARS-CoV-2 in several cohorts. So far, the effect of infection with SARS-CoV-2 on the course...

Full description

Saved in:
Bibliographic Details
Main Authors: Boris Hügle (Author), Manuela Krumrey-Langkammerer (Author), Johannes-Peter Haas (Author)
Format: Book
Published: BMC, 2021-11-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_a1eb01df668049c6ad5771d7cd9f96b2
042 |a dc 
100 1 0 |a Boris Hügle  |e author 
700 1 0 |a Manuela Krumrey-Langkammerer  |e author 
700 1 0 |a Johannes-Peter Haas  |e author 
245 0 0 |a Infection with SARS-CoV-2 causes flares in patients with juvenile idiopathic arthritis in remission or inactive disease on medication 
260 |b BMC,   |c 2021-11-01T00:00:00Z. 
500 |a 10.1186/s12969-021-00653-8 
500 |a 1546-0096 
520 |a Abstract Background Flares of juvenile idiopathic arthritis (JIA) have been described in the context of various infections. Flares of rheumatic diseases in adults have been described following infection with SARS-CoV-2 in several cohorts. So far, the effect of infection with SARS-CoV-2 on the course of JIA is unknown. Methods The database of the German Center for Pediatric and Adolescent Rheumatology was searched for patients with confirmed infection with SARS-CoV-2 and subsequent disease flare, admitted from July 2020 until June 2021. cJADAS-27, ESR and C-reactive protein, as well as uveitis activity, medication at the time of flare and treatment of flare was extracted. Patient cases were described individually. Results Out of 988 patients admitted, five patients with remission off medication (n = 2) or inactive disease on medication (n = 3) were identified, with flare symptoms up to four weeks after infection with SARS-CoV-2. Conclusions Flares can occur after infection with SARS-CoV-2 in patients with JIA in remission or inactive disease on medication. Treating physicians need to be aware of this fact, especially when counseling patients with rheumatic diseases about the respective dangers of COVID-19 and vaccination against SARS-CoV-2. 
546 |a EN 
690 |a Pediatrics 
690 |a RJ1-570 
690 |a Diseases of the musculoskeletal system 
690 |a RC925-935 
655 7 |a article  |2 local 
786 0 |n Pediatric Rheumatology Online Journal, Vol 19, Iss 1, Pp 1-5 (2021) 
787 0 |n https://doi.org/10.1186/s12969-021-00653-8 
787 0 |n https://doaj.org/toc/1546-0096 
856 4 1 |u https://doaj.org/article/a1eb01df668049c6ad5771d7cd9f96b2  |z Connect to this object online.